vTv Therapeutics Initiated with Buy Rating and $67 Price Target
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Source: Benzinga
- Analyst Rating Upgrade: TD Cowen analyst Ritu Baral initiated coverage on vTv Therapeutics Inc (NASDAQ:VTVT) with a Buy rating and a price target of $67, representing significant upside from Friday's close of $39.60, indicating strong market optimism about the company's future growth prospects.
- Positive Market Reaction: Following the analyst rating announcement, vTv Therapeutics' stock is expected to gain traction, with investors showing heightened interest in its potential market performance, which could attract more capital inflow.
- SharpLink Gaming Rating Boost: Cantor Fitzgerald analyst Brett Knoblauch initiated coverage on SharpLink Gaming Inc (NASDAQ:SBET) with an Overweight rating and a price target of $15, indicating a notable increase from Friday's close of $9.69, reflecting recognition of its business growth potential.
- Dual Ratings for Lumexa Imaging: Both Leerink Partners and Jefferies initiated coverage on Lumexa Imaging Holdings Inc (NASDAQ:LMRI) with Outperform ratings and a price target of $23, showcasing a strong consensus in the market regarding the company's promising outlook.
Analyst Views on LMRI
Wall Street analysts forecast LMRI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LMRI is 22.71 USD with a low forecast of 22.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 14.050
Low
22.00
Averages
22.71
High
23.00
Current: 14.050
Low
22.00
Averages
22.71
High
23.00
About LMRI
Lumexa Imaging Holdings, Inc. is a national provider of diagnostic imaging services. The Company offers a range of advanced imaging services (MRI, CT and PET scans) and routine diagnostic and screening imaging services (X-ray, ultrasound and mammography). The Company’s segments include Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The Outpatient segment consists of imaging centers that are owned or operated by it (either wholly owned or via unconsolidated affiliate), where it performs the imaging scan and provides the radiologist’s interpretation service. The Professional segment consists of professional interpretation services, where the imaging scan itself is performed at the hospital or point of care and not by it or its unconsolidated affiliates. The Company and its affiliates operate outpatient imaging center footprint in the United States, spanning 184 centers across 13 states and includes eight joint venture partnerships with health systems.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.








